AMD Publications

Real-world unmet needs in the management of poorly responsive neovascular age-related macular degeneration in Europe: data from the FRB! Registry

Ophthalmology Retina

, (epub)

January 2024

Macular Neovascularization type influence on anti-VEGF intravitreal therapy outcomes in Age-related Macular Degeneration

Ophthalmology. Retina

, (epub)

November 2023

Twenty-four-month real-life treatment outcomes of polypoidal choroidal vasculopathy versus type 1 macular neovascularization in Caucasians

Clinical and Experimental Ophthalmology

November 2023

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion

Eye

April 2023

Outcomes of switching from proactive to reactive treatment after developing advanced central neovascular age-related macular degeneration

Retina

March 2023

Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration

Retina

February 2023

Subretinal fluid may protect against macular atrophy in neovascular age-related macular degeneration: 5 years of follow-up from Fight Retinal Blindness registry

Acta Ophthalmologica

December 2022

Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry

Acta Ophthalmologica

December 2022

Incidence, Risk Factors and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor for Retinal Diseases: Data from the Fight Retinal Blindness! Registry

Ophthalmology Retina

November 2022

Quality of life impact of eye diseases: a Save Sight Registries study

Clinical and Experimental Ophthalmology

May 2022

Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes

Clinical and Experimental Ophthalmology

April 2022

International impact of the COVID-19 pandemic lockdown on intravitreal therapy outcomes: Fight Retinal Blindness registry

Retina

April 2022

Email: ssi.ssr@sydney.edu.au
Phone: (+61) 421 787 808

Level 1, South Block
Sydney Eye Hospital
8 Macquarie Street
Sydney NSW 2000

AMD Publications

Real-world unmet needs in the management of poorly responsive neovascular age-related macular degeneration in Europe: data from the FRB! Registry

Macular Neovascularization type influence on anti-VEGF intravitreal therapy outcomes in Age-related Macular Degeneration

Twenty-four-month real-life treatment outcomes of polypoidal choroidal vasculopathy versus type 1 macular neovascularization in Caucasians

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion

Outcomes of switching from proactive to reactive treatment after developing advanced central neovascular age-related macular degeneration

Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration

Subretinal fluid may protect against macular atrophy in neovascular age-related macular degeneration: 5 years of follow-up from Fight Retinal Blindness registry

Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry

Incidence, Risk Factors and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor for Retinal Diseases: Data from the Fight Retinal Blindness! Registry

Quality of life impact of eye diseases: a Save Sight Registries study

Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes

International impact of the COVID-19 pandemic lockdown on intravitreal therapy outcomes: Fight Retinal Blindness registry

Follow us

Quick links